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Abstract Ulcerative colitis (UC) is thought to originate from
a disbalance in the interplay between the gut microbiota and
the innate and adaptive immune system. Apart from the bac-
terial microbiota, there might be other organisms, such as
parasites or viruses, that could play a role in the aetiology of
UC. The primary objective of this study was to compare the
prevalence of Blastocystis sp. in a cohort of patients with
active UC and compare that to the prevalence in healthy con-
trols. We studied patients with active UC confirmed by endos-
copy included in a randomised prospective trial on the faecal
transplantation for UC. A cohort of healthy subjects who
served as donors in randomised trials on faecal transplantation
were controls. Healthy subjects did not have gastrointestinal
symptoms and were extensively screened for infectious dis-
eases by a screenings questionnaire, extensive serologic as-
sessment for viruses and stool analysis. Potential parasitic in-
fections such as Blastocystis were diagnosed with the triple
faeces test (TFT). The prevalence of Blastocystis sp. were
compared between groups by Chi-square testing. A total of
168 subjects were included, of whom 45 had active UC [me-
dian age 39.0 years, interquartile range (IQR) 32.5–49.0, 49%
male] and 123 were healthy subjects (median age 27 years,
IQR 22.0–37.0, 54 % male). Blastocystis sp. was present in
the faeces of 40/123 (32.5 %) healthy subjects and 6/45
(13.3 %) UC patients (p=0.014). Infection with Blastocystis
is significantly less frequent in UC patients as compared to
healthy controls.
Introduction
The microbiota are believed to play an important role in the
interaction between the host and the immune system. Com-
mensal microbes are believed to protect our body against in-
vading pathogens and have an important function in the de-
velopment of the mucosal immune system [1]. Ulcerative co-
litis (UC) is thought to originate from an uncontrolledmucosal
immune response initiated by luminal microbiota. An aberrant
microbiome in UC has been described in several studies,
characterised by reduced numbers of Firmicutes and
Bacteroidetes, as well as a lower species diversity as com-
pared to controls [2–4]. Besides bacteria however, the gut is
also colonised by viruses (5.8%), archaea (0.8%) and eukary-
otes (0.5 %) [5], although little is known about the relevance
of these microorganisms in UC. One of the eukaryotes that is
still debated with regard to its pathogenic role is Blastocystis
sp.. In the literature, Blastocystis prevalence in asymptomatic
or symptomatic subjects varies from 0.5 % in Japan up to
100 % observed in children living in villages of the Senegal
River Basin [6, 7]. The prevalence of Blastocystis sp. was
studied in patients with irritable bowel syndrome (IBS) for a
possible causative relation with abdominal symptoms and the
presence of Blastocystis [8, 9]. In inflammatory bowel disease
(IBD), the question remains as to whether eradication of an
infection with Blastocystis would relieve abdominal symp-
toms such as abdominal pain or bloating [10, 11]. Conflicting
data exist on the role of this eukaryote in either disease [12,
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13]. Recently, a study was performed on Blastocystis infection
and the association with the microbiota. Interestingly,
Blastocystis was found to be associated with a decrease of
faecal microbiota protective bacteria, such as Bifidobacterium
sp. and Faecalibacterium prausnitzii [8].
The aim of our study was to compare the prevalence of
Blastocystis sp. in a well-defined cohort of patients with active
UC to a cohort of healthy controls.
Materials and methods
UC patients and healthy volunteers
Patients with active UC participating in a clinical trial between
23-5-2011 and 30-06-2013 were included if they had an ex-
acerbation of their disease, defined by a Simple Clinical Co-
litis Activity Index (SCCAI) score of ≥4 and ≤11 [14]. Endo-
scopic activity was confirmed by an endoscopic Mayo score
of ≥1. Patients were allowed to use a stable dose of medication
for UC, except for biologicals or corticosteroids >10 mg per
day, and had not used antibiotics in the 6 weeks before inclu-
sion. Healthy volunteers were involved in one of the faecal
microbiota transplantation (FMT) trials at our study centre
from 2008 to 2013. They participated as faecal donors and
were regarded as a control cohort. We collected all clinical
and screening data. These volunteers were screened for faecal
donation in either a clinical faecal transplantation trial on FMT
in UC, type I diabetes, type II diabetes/metabolic syndrome or
for patients suffering from recurrent Clostridium difficile in-
fection [15]. Healthy volunteers were relatives of the patients
or unrelated volunteers working or studying at the university
hospital centre and were required to be completely free of
gastrointestinal symptoms. They were extensively
interviewed on sexual risk behaviour and recent travel behav-
iour by a detailed questionnaire. Donors were excluded if they
had travelled to a developing country within 6 months before
screening or if they were suspected of sexual risk behaviour.
Use of antibiotics in the previous 8 weeks was also considered
an exclusion criterium. A gastrointestinal infection was ruled
out by faecal tests on pathogenic bacteria, parasites and virus-
es [enteropathogenic bacteria: Salmonella, Shigella, Yersinia
enterocolitica and Campylobacter, evaluated by local stan-
dards, Clostridium difficile, evaluated by toxin enzyme-
linked immunosorbent assay (ELISA) and culture; entero-
pathogenic parasites, including Blastocystis sp. and
Dientamoeba fragilis, evaluated by the triple faeces test
(TFT), as described below; viruses, including norovirus, rota-
virus, astrovirus, adenovirus, enterovirus, parechovirus and
sapovirus, evaluated by real-time TaqMan polymerase chain
reaction (PCR) using the Roche LightCycler 480 instrument
[16]] in both healthy volunteers and UC patients.
The study protocol was approved by the Medical Ethical
Committee of the Academic Medical Center in Amsterdam,
the Netherlands (METC registry number #2011_005). All
subjects signed an informed consent form.
Faecal tests on Blastocystis sp
The TFT was used for the diagnosis of intestinal parasites,
including Blastocystis sp. [17, 18]. In this test stool, samples
of a patient are collected in three tubes on three consecutive
days before delivery in the hospital. In two of the three tubes,
on day 1 and day 3, a preservation sodium acetate–acetic
acid–formalin (SAF) solution is present, with which vegeta-
tive stages of protozoa, including Blastocystis sp., are well
preserved. With the tube from the second day, a fresh, non-
conserved, stool sample is collected. Samples which are fixed
in SAF are examined with wet smears and chlorazol black
permanent stain. Fresh stool from the second day is concen-
trated according to Ridley and the sediment microscopically
examined for cysts of protozoa and eggs of helminths. The
results of microscopic examinations of all three samples are
combined to provide the final result of the TFT test of the
patient. As diagnostic criterion for positivity of a sample for
Blastocystis sp., at least two clear vacuolar forms in either of
the two SAF-fixed samples had to be present. Granular or
amoeboid stages of Blastocystis sp. were not studied. As di-
agnostic criteria for positivity of a sample for Dientamoeba
fragilis, at least two clear vacuolar forms in either of the two
SAF-fixed samples had to be present. The diagnosis was con-
firmed by a chlorazol black dye permanent stain.
Statistical analysis
Based on an expected absolute difference in prevalence rates of
30 % (30 % vs. 60 %), a desired power of 80 % and a two-sided
α-level of 0.05, 50 subjects per group were calculated for pri-
mary analyses. Data were expressed as the mean and 95 %
confidence interval (CI) of the mean or, when they were not
normally distributed, as the median and interquartile range
(IQR). The prevalence rates of Blastocystis sp., diagnosed by
the TFT, between study groups were compared by Chi-square
testing if the expected cell size was >5, and by Fisher’s exact test
in case of smaller cell sizes. A p-value <0.05 was considered
statistically significant. Statistical analyseswere performed using
SPSS version 21.0 software (SPSS Inc., Chicago, IL, USA).
Results
Forty-five UC patients and 123 healthy subjects were studied.
The recruitment periods were randomly distributed between
summer and winter for both groups. Forty-four percent of UC
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patients (n=20) and 50 % of healthy subjects (n=62) were
included from the winter period (October–March). Forty-six
percent of UC patients (n=25) and 50 % of healthy subjects
were included during summer (n=61). Gender was equally
distributed across groups. Healthy subjects were younger than
the included UC patients (p<0.001). The median disease dura-
tion of UC was 9 years (IQR 0–27). According to the Montreal
classification, UC patients were classified as: proctitis (n=3,
6.7 %), left-sided colitis (n=24, 53.3 %) or pancolitis (n=18,
40.0 %), as the most severe ever documented. In all UC pa-
tients, mucosal disease activity was confirmed by endoscopy.
Seven patients (15.6%) had an active proctitis, 28 (62.2 %) had
a left-sided colitis and 10 (22.2%) had a pancolitis. Themedian
SCCAI score, assessing clinical activity, was 8 (IQR 4–11).
None of the included healthy subjects or UC patients turned
out to have an infection with bacterial, viral or parasitic patho-
gens. The characteristics of the study population and medica-
tion use at inclusion are shown in Table 1.
Prevalence of Blastocystis sp. in UC patients and healthy
controls
Six of the 45 UC patients (13 %) had a positive TFT test for
Blastocystis sp. versus 40 of the 123 (33 %) healthy controls
(p=0.014) (Table 2). Blastocystis sp. infection was equally
distributed across UC patients with proctitis, left-sided colitis
and pancolitis (Table 2), p=0.20. None of the treatments that
the UC patients were receiving for their UC (mesalamine,
immunosuppressants, corticosteroids) was associated with
higher infection rates with Blastocystis sp. (data not shown).
No significant differences were found when comparing the
proportion of infected female subjects [vs. the proportion of
infected male patients per group (Table 2)], p=0.41 for UC
patients and p=0.64 for healthy controls. In a multivariate
logistic regression analysis corrected for age, healthy controls
had a 2.86 odds ratio (95 % CI 1.09–7.53, p=0.03) for
Blastocystis infection compared to UC patients.
Other intestinal protozoa observed in the UC population
included Dientamoeba fragilis. There was no significant dif-
ference in the prevalence of Dientamoeba fragilis between
UC patients [6 out of 45 (13 %) were found to be positive]
and healthy controls [27 out of 123 (22 %) were found to be
positive], p=0.21.
Discussion
This study reports on the prevalence of Blastocystis sp. in
patients with clinical and endoscopic active UC compared to
a well-defined cohort of healthy controls, determined by the
use of the TFT. Infection with Blastocystis sp. was significant-
ly less frequent (13.3 %) in UC patients compared to healthy
controls (32.5 %), p=0.014.
Health is a status which is hard to define without specific
markers available. We compared patients with active UC and
healthy controls using strict predefined definitions of the stud-
ied subjects. Healthy controls were extensively questioned on
any risk for infection due to sexual risk behaviour or travelling
to developing countries. Only if they were not suspect for any
Table 1 Characteristics of the
study population UC patients, n=45 Healthy controls, n=123 p-Value
Male, n (%) 22 (49) 67 (54) 0.601
Proctitis, n (%) 3 (6.7) − n/a
Left-sided colitis, n (%) 24 (53.3) − n/a
Pancolitis, n (%) 18 (40.0) − n/a
Age, years (median, IQR) 39 (32.5–49.0) 27 (22.0–37.0) <0.001
Disease duration, years (median, IQR) 9 (0–27) − n/a
Medication, n (%) 29 (64.4 %) 0 (0) n/a
Mesalamine oral, n (%) 29 (64.4 %) − n/a
Mesalamine/corticosteroids rectal, n (%) 13 (28.9 %) − n/a
Immunosuppressants (thiopurine), n (%) 13 (28.9 %) − n/a
Corticosteroids, systemic, n (%) 9 (20.0 %) − n/a
Table 2 Prevalence of Blastocystis sp. for ulcerative colitis (UC)






Positive for Blastocystis sp.,
n (%)
6 (13) 40 (33) 0.014*
Male, n (%) 2 (33) 23 (58) 0.38**
Proctitis, n (%) 1 (2) −
Left-sided colitis, n (%) 4 (9) −
Pancolitis, n (%) 1 (2) −
*Chi-square test
**Fisher’s exact probability test
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risk behaviour were they selected for faecal and serologic
screening on pathogens (either bacterial, viral or parasitic).
In UC patients, infectious causes of an exacerbation of disease
were ruled out according to the same screening procedure.
None of the included healthy subjects or UC patients turned
out to have an infection with bacterial, viral or parasitic path-
ogens. In the available literature on Blastocystis sp., ‘healthy
subjects’ were not characterised by the absence of infectious
diseases or could be on chronic medication. Scanlan et al.
performed a study on Blastocystis prevalence in a group of
105 healthy individuals comparable to the current sample size
of 123 healthy controls [19]. They were not reported to be
symptomatic or not. Besides that, subjects >65 years of age
derived from a hospital setting will not be the optimal
‘healthy’ population to study. In the current study, strict defi-
nition of both study groups made possible a clear comparison
of the true prevalence of Blastocystis sp. in both UC patients
and healthy controls. Whereas we did not find medication to
be associated with the presence or absence of Blastocystis sp.
in UC patients, it is hard to exclude any role for medication
that was only used in UC patients and not by subjects in the
control group. Both the TFT and PCR are highly reliable for
the diagnosis of Blastocystis sp. Microscopy by the TFT was
slightly superior in terms of sensitivity than PCR as tested in
the stools of 107 patients [18].
When comparing the current study to previously published
data, it is important to take into account that there are several
factors potentially influencing the prevalence of Blastocystis
infections. Examples are the indication for the test: studying
symptomatic patients or asymptomatic subjects; preservation
of faecal material; and the diagnostic procedures used for par-
asite testing (PCR or TFT). Even by using the same PCR
technique for the detection of Blastocystis sp., the sensitivity
is dependent on the commercial DNA extraction kit used [20].
Also, among microscopy procedures, conventional staining
procedures such as Lugol’s stain and trichrome staining
showed lower sensitivity compared to immunofluorescence
antibody (IFA) staining using an immunofluorescent antibody
for Blastocystis [21]. Age was studied to be of influence on the
incidence of Blastocystis infection. A study performed on
healthcare-seeking patients in Karachi showed an age distri-
bution with a relatively high prevalence at middle age com-
pared to young adults [22]. Older age was found to be asso-
ciated with Blastocystis infection as observed in primary care
patients diagnosed with IBS and aged 18–50 years from Den-
mark [23]. This observation was also found in an Australian
population of patients positive for an enteric protozoan infec-
tion [24]. A comparable prevalence of Blastocystis sp. was
found in healthy subjects >65 years of age to subjects
<65 years of age, as described by Scanlan at al [19]. The
association of age and Blastocystis was not well studied in
UC patients. In our study, UC patients were older than healthy
controls. Multivariate analysis revealed that age was not a
predictor for Blastocystis positivity. If older age would be
associated with a higher prevalence of Blastocystis sp. also
in UC patients, the observed difference in prevalence would
be even greater if both study groups were age-matched. Fur-
thermore, environmental factors such as hygienic circum-
stances and the geographical location under study play a role
in the outcome of prevalence studies on Blastocystis sp.
In a case–control study comparing the prevalence of
Blastocystis sp. by applying native Lugol and formol-ethyl ace-
tate concentration to stool specimens in patients with IBD and
IBS as opposed to asymptomatic healthy controls, a higher prev-
alence of Blastocystis sp. was detected in UC patients [13]. Con-
versely, a study performed by Petersen et al., in which a PCRwas
used to diagnose Blastocystis, suggested that active UC patients
showed a lower prevalence of Blastocystis sp. andDientamoeba
fragilis infection compared to healthy controls [25].
Relatively high prevalence rates of Blastocystis infection
(32.5 %) were observed in our healthy control group. In com-
parison to a study we performed on 442 patient samples from
routine clinical parasitology, 24.0 % tested positive with the
TFT for Blastocystis sp. [18], which is lower than the observed
prevalence of 32.5 % in the current cohort of healthy controls.
Of note, the prevalences in both the healthy control group and
UC patients in the present study are higher than those observed
by Petersen et al. (healthy controls: 32.5 % by TFT vs. 19 %
with PCR in two cohorts of medical and laboratory staff and
recruits; UC patients: 13 % by TFT vs. 0 % with PCR with
Petersen et al. [25]). Nevertheless, one should be cautious when
comparing data measured by different diagnostic approaches.
All UC patients in our study had an exacerbation of their
disease. Prevalence rates were not compared with a UC cohort
of patients in remission. Petersen et al. observed that
Blastocystis infection was significantly less prevalent in UC
patients with active disease compared to patients with inactive
disease. This phenomenon was not observed in active and
inactive Crohn’s disease patients [25].
In our study, we found a lower prevalence of Blastocystis
measured by a highly sensitive technique such as microscopy
in UC patients as compared to a large cohort of healthy sub-
jects. This observation supports the hygiene hypothesis sug-
gesting that the increase in chronic inflammatory disorders is
at least partly attributable to immune dysregulation. This
might result from the lack of exposure to microorganisms that
help to establish the ‘normal’ background levels of immune
regulation [26]. From mouse models, we learned that germ-
free animals fail to develop spontaneous colitis [27]. There is
growing evidence that disturbances in the bacterial microbiota
result in immunological dysregulation that may underlie dis-
orders such as IBD [28]. Alternatively, Blastocystis sp. may be
more sensitive to the inflammatory conditions in UC patients,
leading to the parasite being cleared by UC patients more
often than by healthy controls. Hopefully, metagenomic ap-
proaches will not only yield more insight into the role of the
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microbiota in health and disease, but may also elucidate the
complex network of microorganisms being part of the gastro-
intestinal tract.
The pathogenicity of Blastocystis has been debated multi-
ple times, but no consensus has been achieved as to whether
this organism is related to intestinal symptoms such as nausea,
abdominal pain and diarrhoea [29–31]. We did not aim to
answer any question regarding the relationship between the
presence of Blastocystis sp. and intestinal symptoms in UC
patients in the current study. Notwithstanding, the high prev-
alence observed in asymptomatic healthy controls points to a
commensal immunoregulatory role for these parasites. As ab-
errancies in the intestinal microbiota are found in UC patients,
it still remains unknown whether this is a cause or a
consequence of chronic inflammation. From this perspec-
tive, it would be interesting to investigate whether the ob-
served low prevalence of Blastocystis sp. was present already
during childhood and may persist after UC diagnosis. FMT
with faeces from a healthy donor can potentially restore the
low-diversity faecal microbiota in UC. Future studies should
investigate whether the occurrence of Blastocystis increases
after FMT. FMTwould be an interesting model to investigate
whether microbiota changes come along with a different com-
munity attractive for Blastocystis sp.
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